B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients

Abstract

Non-invasive B-cell imaging by ⁸⁹Zr-rituximab PET-CT has promising clinical value to select RA responders to rituximab at baseline. ⁸⁹Zr-rituximab PET-CT may also hold promise for monitoring anti-B-cell therapies in other B-cell driven autoimmune diseases, such as systemic lupus erythematosus and Sjögren's disease.